+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Colorectal Cancer Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5734961
The colorectal cancer drugs market size has grown strongly in recent years. It will grow from $19.51 billion in 2023 to $20.74 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth observed in the historical period can be attributed to factors such as the integration of multimodal approaches, the introduction of chemotherapy, advancements in surgical techniques, the emergence of targeted therapies, and the contributions from clinical trials and research efforts.

The colorectal cancer drugs market size is expected to see strong growth in the next few years. It will grow to $26.39 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to the rise in personalized treatment approaches, the adoption of patient-centric care models, the expansion of targeted therapies, increased adoption of combination therapies, and the acceleration of regulatory processes. Major trends expected in the forecast period include advancements in immunotherapy, the evolution of precision medicine, the exploration and application of combination therapies, research and utilization of biomarkers, and innovations in clinical trials.

The anticipated surge in demand for personalized medicines is poised to drive the growth of the colorectal cancer drugs market. Personalized medicine, also referred to as precision medicine, adopts an approach that considers individual variations in genes, environments, and lifestyles for medical treatment. This approach is revolutionizing the treatment of colorectal cancer (CRC), providing more tailored and effective care. As research and drug development align with specific genetic and molecular profiles, the colorectal cancer drugs market is expected to grow. The availability of over 75,000 genetic testing products and 300 personalized medicines, as reported in October 2022 by STAT, underscores the increasing demand for personalized medicine, contributing to the market's growth.

The colorectal cancer drugs market is also expected to witness growth due to the escalating number of clinical trials. Clinical trials, involving human volunteers, evaluate the safety and efficacy of various medical treatments, including drugs designed for colorectal cancer treatment. These trials play a crucial role in identifying novel therapies that can enhance patient outcomes, potentially introducing new drugs to the market. The substantial increase in the number of clinical trials, with over 452,000 registered studies and more than 64,000 actively seeking participants, as reported by Xtalks in May 2023, indicates a significant rise compared to early 2021. This surge in clinical trials is contributing to the growth of the colorectal cancer drugs market.

The use of biologics and targeted therapies poses a restraint on the colorectal cancer drugs market. Biologic therapy harnesses the body's immune system to combat cancer, potentially reducing immune power, while targeted therapies block cancer growth and spread. Despite their advantages, such as specificity to cancer cells and efficacy in advanced stages, these therapies may negatively impact the market by affecting the growth of conventional chemical drugs. The evolving landscape of targeted therapies, including hormone therapies, gene expression modulators, apoptosis inducers, and immunotherapies, signifies a shift in colorectal cancer treatment.

Major companies in the colorectal cancer drugs market are focused on gaining FDA approvals for new drugs to enhance profitability. An example is LONSURF (trifluridine/tipiracil), an oral prescription medication approved by the FDA for treating specific cancers such as colon, rectal, and stomach cancer that has metastasized. Taiho Pharmaceutical Co. Ltd. announced FDA approval for LONSURF in combination with bevacizumab for treating metastatic colorectal cancer in August 2023. The combination significantly increased overall and progression-free survival compared to LONSURF alone.

In October 2023, the Bristol-Myers Squibb Company acquired Mirati Therapeutics Inc for $5.8 billion. This strategic move aimed to add KRAZATI, a prominent lung cancer drug, to Bristol Myers Squibb's commercial portfolio, enhancing and diversifying its oncology offerings. The acquisition aligns with Bristol-Myers Squibb's mission to uncover scientific advancements that promise a life free from cancer. Mirati Therapeutics Inc., a US-based biotech company, contributes valuable therapies to Bristol-Myers Squibb's efforts in the field of oncology.

Major companies operating in the colorectal cancer drugs market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Danaher Corporation, Eli Lilly and Company, Amgen Inc., Siemens Healthineers AG, Astellas Pharma Inc., Servier Laboratories, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Ipsen SA, Taiho Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Metabiomics Corporation, Randox Laboratories, Taiho Oncology Inc., EDP Biotech Corporation, Genomic Tree Inc., Ono Pharmaceutical Co. Ltd., Epigenomics AG, Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mundipharma International Limited, Teva Pharmaceutical Industries Ltd., Biogen Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.

North America was the largest region in the colorectal cancer drugs market in 2023. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the colorectal cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of drugs used for colorectal cancer treatment include vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators. Vascular endothelial growth factor (VEGF) inhibitors are drugs that block VEGF and VEGFR activity. The different classes of drugs include immunotherapy, chemotherapy, and others, and these medications are typically dispensed through hospital pharmacies, retail pharmacies, and other distribution channels.

The colorectal cancer drugs market research report is one of a series of new reports that provides colorectal cancer drugs market statistics, including colorectal cancer drugs industry global market size, regional shares, competitors with a colorectal cancer drugs market share, detailed colorectal cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer drugs industry. This colorectal cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The colorectal cancer drugs market consists of sales of avastin, bevacizumab, and camptosar. Values in the colorectal cancer drugs market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary2. Colorectal Cancer Drugs Market Characteristics3. Colorectal Cancer Drugs Market Trends and Strategies
4. Colorectal Cancer Drugs Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Colorectal Cancer Drugs Market Size and Growth
5.1. Global Colorectal Cancer Drugs Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Colorectal Cancer Drugs Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Colorectal Cancer Drugs Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Colorectal Cancer Drugs Market Segmentation
6.1. Global Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Vascular Endothelial Growth Factor (VEGF) Inhibitors
  • Epidermal Growth Factor Receptor (EGFR) Inhibitors
  • Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
  • BRAF or MEK Inhibitors
  • Tyrosine Kinase (TKI) Inhibitors
  • Immunomodulators
6.2. Global Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Immunotherapy
  • Chemotherapy
  • Other Classes
6.3. Global Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels
7. Colorectal Cancer Drugs Market Regional and Country Analysis
7.1. Global Colorectal Cancer Drugs Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Colorectal Cancer Drugs Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Colorectal Cancer Drugs Market
8.1. Asia-Pacific Colorectal Cancer Drugs Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Colorectal Cancer Drugs Market
9.1. China Colorectal Cancer Drugs Market Overview
9.2. China Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Colorectal Cancer Drugs Market
10.1. India Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Colorectal Cancer Drugs Market
11.1. Japan Colorectal Cancer Drugs Market Overview
11.2. Japan Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Colorectal Cancer Drugs Market
12.1. Australia Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Colorectal Cancer Drugs Market
13.1. Indonesia Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Colorectal Cancer Drugs Market
14.1. South Korea Colorectal Cancer Drugs Market Overview
14.2. South Korea Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Colorectal Cancer Drugs Market
15.1. Western Europe Colorectal Cancer Drugs Market Overview
15.2. Western Europe Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Colorectal Cancer Drugs Market
16.1. UK Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Colorectal Cancer Drugs Market
17.1. Germany Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Colorectal Cancer Drugs Market
18.1. France Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Colorectal Cancer Drugs Market
19.1. Italy Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Colorectal Cancer Drugs Market
20.1. Spain Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Colorectal Cancer Drugs Market
21.1. Eastern Europe Colorectal Cancer Drugs Market Overview
21.2. Eastern Europe Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Colorectal Cancer Drugs Market
22.1. Russia Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Colorectal Cancer Drugs Market
23.1. North America Colorectal Cancer Drugs Market Overview
23.2. North America Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Colorectal Cancer Drugs Market
24.1. USA Colorectal Cancer Drugs Market Overview
24.2. USA Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Colorectal Cancer Drugs Market
25.1. Canada Colorectal Cancer Drugs Market Overview
25.2. Canada Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Colorectal Cancer Drugs Market
26.1. South America Colorectal Cancer Drugs Market Overview
26.2. South America Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Colorectal Cancer Drugs Market
27.1. Brazil Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Colorectal Cancer Drugs Market
28.1. Middle East Colorectal Cancer Drugs Market Overview
28.2. Middle East Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Colorectal Cancer Drugs Market
29.1. Africa Colorectal Cancer Drugs Market Overview
29.2. Africa Colorectal Cancer Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Colorectal Cancer Drugs Market, Segmentation by Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Colorectal Cancer Drugs Market, Segmentation by Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Colorectal Cancer Drugs Market Competitive Landscape and Company Profiles
30.1. Colorectal Cancer Drugs Market Competitive Landscape
30.2. Colorectal Cancer Drugs Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Merck & Co. Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. AbbVie Inc.
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Bayer AG
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Novartis AG
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Colorectal Cancer Drugs Market Other Major and Innovative Companies
31.1. Sanofi SA
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca plc
31.4. Abbott Laboratories
31.5. GlaxoSmithKline plc
31.6. Takeda Pharmaceutical Company Limited
31.7. F. Hoffmann-La Roche Ltd.
31.8. Danaher Corporation
31.9. Eli Lilly and Company
31.10. Amgen Inc.
31.11. Siemens Healthineers AG
31.12. Astellas Pharma Inc.
31.13. Servier Laboratories
31.14. Eisai Co. Ltd.
31.15. Sumitomo Dainippon Pharma Co. Ltd.
32. Global Colorectal Cancer Drugs Market Competitive Benchmarking33. Global Colorectal Cancer Drugs Market Competitive Dashboard34. Key Mergers and Acquisitions in the Colorectal Cancer Drugs Market
35. Colorectal Cancer Drugs Market Future Outlook and Potential Analysis
35.1 Colorectal Cancer Drugs Market in 2028 - Countries Offering Most New Opportunities
35.2 Colorectal Cancer Drugs Market in 2028 - Segments Offering Most New Opportunities
35.3 Colorectal Cancer Drugs Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Colorectal Cancer Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on colorectal cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for colorectal cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors; Epidermal Growth Factor Receptor (EGFR) Inhibitors; Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors; BRAF or MEK Inhibitors; Tyrosine Kinase (TKI) Inhibitors; Immunomodulators
2) By Class: Immunotherapy; Chemotherapy; Other Classes
3) By Distribution Channels: Hospitals Pharmacies; Retail Pharmacies; Other Distribution Channels

Key Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc.
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Eli Lilly and Company
  • Amgen Inc.
  • Siemens Healthineers AG
  • Astellas Pharma Inc.
  • Servier Laboratories
  • Eisai Co. Ltd.
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Ipsen SA
  • Taiho Pharmaceutical Co. Ltd.
  • Kyowa Kirin Co. Ltd.
  • Metabiomics Corporation
  • Randox Laboratories
  • Taiho Oncology Inc.
  • EDP Biotech Corporation
  • Genomic Tree Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Epigenomics AG
  • Daiichi Sankyo Company Limited
  • Otsuka Pharmaceutical Co. Ltd.
  • Mundipharma International Limited
  • Teva Pharmaceutical Industries Ltd.
  • Biogen Inc.
  • Gilead Sciences Inc.
  • Johnson & Johnson Services Inc.
  • Spectrum Pharmaceuticals Inc.
  • Exelixis Inc.
  • Seattle Genetics Inc.
  • Incyte Corporation
  • Clovis Oncology Inc.
  • Karyopharm Therapeutics Inc.

Methodology

Loading
LOADING...

Table Information